Isabella Ciccone, Assistant Editor, NeurologyLive®, has been with the team since September 2022. Follow her on Twitter @iciccone7 or email her at iciccone@mjhlifesciences.com
Extended-Release Amantadine Shows Reduction in Dyskinesia Severity for Parkinson Disease
October 1st 2024Amantadine extended-release capsules, approved for levodopa-related dyskinesia and OFF episodes in Parkinson disease, offer high amantadine concentrations that peak in the time of first morning levodopa dose.
NeurologyLive® Clinician of the Month Spotlight: Forum Kamdar, MD, PhD, FACC, FHFSA
September 30th 2024As part of our monthly clinician spotlight, NeurologyLive® highlighted neuromuscular-associated cardiomyopathy expert Forum Kamdar, MD, PhD, FACC, FHFSA, an advanced heart failure physician-scientist at the University of Minnesota.
A Melting Pot of Strategies and Collaboration at the 2025 MDA Conference: Sharon Hesterlee, PhD
September 26th 2024The chief research officer of the Muscular Dystrophy Association talked about what is to be expected at the 2025 MDA Conference, held March 16-19, in Dallas, Texas. [WATCH TIME: 5 minutes]
FDA Approves Zevra Therapeutics’ Arimoclomol as First Treatment for Niemann-Pick Disease Type C
September 25th 2024Zevra Therapeutics plans to immediately start its launch activities for arimoclomol, marketed as Miplyffa, which is anticipated to be commercially available in 8 to 12 weeks in the United States.
Using the DAAE Score to Advance Personalized Medicine for Multiple Sclerosis: Tom Fuchs, MD, PhD
September 25th 2024The postdoctoral researcher at Amsterdam University Medical Center talked about the DAAE score 2.0 which offers an improved, validated clinical tool to predict the risk of transitioning to secondary progressive multiple sclerosis. [WATCH TIME: 5 minutes]
A Clinical Approach to Recognizing and Diagnosing Restless Leg Syndrome: Shalini Paruthi, MD, FAASM
September 23rd 2024In honor of Restless Legs Syndrome Awareness Day, held September 23, 2024, the American Academy of Sleep Medicine spokesperson talked about the condition and its impact on the United States population as well as the criteria to diagnose it. [WATCH TIME: 3 minutes]
Evolving Understanding and Treatment of Smoldering Multiple Sclerosis: Antonio Scalfari, MD, PhD
September 15th 2024The consultant neurologist at Imperial College Healthcare Trust discussed how smoldering MS challenges traditional views of disease progression, seeking combined therapies targeting both inflammatory activity and mechanisms driving smoldering-associated worsening. [WATCH TIME: 4 minutes]